Novo Nordisk A/S vs Tyson Foods, Inc. — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Tyson Foods, Inc. trades at $57.25 (market cap $20.42B). The key difference: Novo Nordisk A/S is far larger — about 10.8× Tyson Foods, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TSN | |
|---|---|---|
Market Cap | $220.53B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $71.70 | $68.75 |
52-Week Low | $35.29 | $50.72 |
Enterprise Value | $239.49B | $28.01B |
Dividend Yield | 3.63% | 3.52% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →